# EDGAR Filing Document

**Accession Number:** 0001776985
**File Stem:** 0001776985-26-000030
**Filing Date:** 2026-5
**Character Count:** 83517
**Document Hash:** 9e6ad793c8d4aad0962b79fd4ea95bf5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001776985-26-000030.hdr.sgml**: 20260505

**ACCESSION NUMBER**: 0001776985-26-000030

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 31

**CONFORMED PERIOD OF REPORT**: 20260505

**FILED AS OF DATE**: 20260505

**DATE AS OF CHANGE**: 20260505

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BioNTech SE
- **CENTRAL INDEX KEY:** 0001776985
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** 2M
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39081
- **FILM NUMBER:** 26940296

**BUSINESS ADDRESS:**
- **STREET 1:** AN DER GOLDGRUBE 12
- **CITY:** MAINZ
- **STATE:** 2M
- **ZIP:** 55131
- **BUSINESS PHONE:** 0049613190840

**MAIL ADDRESS:**
- **STREET 1:** AN DER GOLDGRUBE 12
- **CITY:** MAINZ
- **STATE:** 2M
- **ZIP:** 55131

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

<br>**FORM 6-K** 

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16** 

**UNDER THE SECURITIES EXCHANGE ACT OF 1934** 

**FOR THE MONTH OF MAY 2026**

**COMMISSION FILE NUMBER 001-39081** 

**BioNTech SE**<br> (Translation of registrant's name into English)

**An der Goldgrube 12**

**D-55131 Mainz**

**Germany**

**+49 6131-9084-0**<br> (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

------

**DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K**

On May 5, 2026, BioNTech SE (the "Company") issued a press release announcing its first quarter 2026 financial results and corporate update and details of a conference call to be held at 8:00 am EDT on May 5, 2026 to discuss the results. The press release and the conference call presentation are attached as Exhibits 99.1 and 99.2, respectively, and incorporated by reference herein.

The information contained in Exhibits 99.1 and 99.2 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing.

------

**SIGNATURE**

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| **BioNTech SE** | **BioNTech SE** | | |
| By: | /s/ Ramón Zapata-Gomez | By: | /s/ Dr. Sierk Poetting |
|  | Name: Ramón Zapata-Gomez |  | Name: Dr. Sierk Poetting |
|  | Title: Chief Financial Officer |  | Title: Chief Operating Officer |

---

Date: May 5, 2026

------

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| <u>Exhibit</u> | <u>Description of Exhibit</u> |
| 99.1 | <u>[BioNTech Announces First Quarter 2026 Financial Results and Corporate Update](a991_bntxq12026pressreleas.htm)</u> |
| 99.2 | <u>[First Quarter 2026: Corporate Update and Financial Results](a992bntx1q2026presentati.htm)</u> |

---

## Exhibit 99.1

**Exhibit 99.1**

![image_0a.jpg](image_0a.jpg)

**BioNTech Announces First Quarter 2026 Financial Results and Corporate Update**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* ***Five additional pivotal trials for pumitamig initiated during 2026*** *in collaboration with Bristol Myers Squibb*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* ***Oncology pipeline strength and combination strategy highlighted*** *through multiple clinical data updates, including pumitamig, gotistobart and antibody-drug conjugate programs*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* ***Catalyst-rich year ahead with six late-stage pipeline data readouts expected*** *across immunomodulators, antibody-drug conjugate and mRNA cancer immunotherapies*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* ***COVID-19 2026/2027 season variant-adapted vaccine*** *development and commercial preparation underway*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* ***Operational efficiency to be enhanced through manufacturing footprint consolidation****, supporting strategic capital allocation to further advance its growing oncology pipeline toward commercialization* 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* ***First quarter 2026 revenues of €118.1 million***<sup>1</sup>*, net loss of €531.9 million (adjusted*<sup>2</sup> *net loss of €494.6 million), with diluted loss per share of €2.10 ($2.46*<sup>3</sup>*) (adjusted*<sup>2</sup> *diluted loss per share of €1.95 ($2.28*<sup>3</sup>*))*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* ***Reaffirmed full year 2026 financial guidance and strong financial position*** *continue to de-risk execution with cash, cash equivalents and security investments of €16.8 billion*<sup>4</sup>

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*•* ***Share repurchase program*** *of up to $1.0 billion over twelve months planned* 

**Conference call and webcast scheduled for May 5, 2026, at 8:00 a.m. ET (2:00 p.m. CET)**

**MAINZ, Germany, May 5, 2026 (GLOBE NEWSWIRE)** -- <u>BioNTech SE</u> (Nasdaq: BNTX, "BioNTech" or "the Company") today reported financial results for the three months ended March 31, 2026 and provided an update on its corporate progress.

"In the first quarter, we made substantial progress in executing towards our oncology strategy, highlighted by data presentations from our priority pan-tumor program pumitamig as well as our versatile antibody-drug conjugate portfolio. Simultaneously, we continue to broaden our clinical programs to include novel-novel combinations in order to inform the optimal set-up for registrational combination trials and maximize the potential of our pipeline," said **Prof. Ugur Sahin, M.D., Chief Executive Officer and Co-Founder of BioNTech**. "We will continue to focus on accelerating our key strategic programs as we remain steadfast in our vision to translate our science into survival for patients living with cancer."

**Financial Review for First Quarter 2026**

---

| | | | | |
|:---|:---|:---|:---|:---|
| *in millions €,* <br>*except per share data* | **First Quarter 2026** | **First Quarter 2026** | **First Quarter 2025** | **First Quarter 2025** |
| *in millions €,* <br>*except per share data* | **IFRS Results** | **Adjusted Results**<sup>2</sup> | **IFRS Results** | **Adjusted Results**<sup>2</sup> |
| **Revenues** | 118.1 | 118.1 | 182.8 | 182.8 |
| **Net loss** | (531.9) | (494.6) | (415.8) | (430.8) |
| **Diluted loss per share** | (2.10) | (1.95) | (1.73) | (1.79) |

---

**Revenues** for the first quarter of 2026 were €118.1 million, compared to €182.8 million for the comparative prior year period. The decrease was primarily driven by lower revenues of BioNTech's COVID-19 vaccines.

**Research and development ("R&D") expenses** were €557.0 million for the first quarter of 2026, compared to €525.6 million for the comparative prior year period. R&D expenses were mainly driven by higher expenses for the development of immuno-oncology ("IO") and antibody-drug conjugate

------

![image_0a.jpg](image_0a.jpg)

("ADC") programs, in particular pumitamig and gotistobart, as well as costs from operations of entities acquired during 2025, BioNTech China (previously Biotheus) and CureVac, and an impairment of an intangible asset. These effects were partly offset by lower R&D expenses related to the Company's COVID-19 vaccine collaboration with Pfizer Inc. ("Pfizer").

**Adjusted R&D expenses** were €527.1 million for the first quarter of 2026, compared to €525.6 million for the comparative prior year period. For the first quarter of 2026, adjusted R&D expenses exclude the impairment of an intangible asset.

**Sales, general and administrative ("SG&A") expenses**<sup>5</sup> were €150.8 million for the first quarter of 2026, compared to €120.6 million for the comparative prior year period. The increase was mainly driven by the ongoing commercial build-up and the inclusion of operations of entities acquired in 2025, BioNTech China (previously Biotheus) and CureVac. These costs were partly offset by a reduction in external services.

**Net loss** was €531.9 million for the first quarter of 2026, compared to a net loss of €415.8 million for the comparative prior year period.

**Adjusted net loss** was €494.6 million for the first quarter of 2026, compared to an adjusted net loss of €430.8 million for the comparative prior year period.

**Diluted loss per share** was €2.10 for the first quarter of 2026, compared to a diluted loss per share of €1.73 for the comparative prior year period.

**Adjusted diluted loss per share** was €1.95 for the first quarter of 2026, compared to adjusted diluted loss per share of €1.79 for the comparative prior year period.

**Cash, cash equivalents and security investments** as of March 31, 2026, were €16,763.3 million, comprising €9,939.4 million in cash and cash equivalents, €4,696.9 million in current security investments disclosed as financial assets and €2,127.0 million in non-current security investments disclosed as financial assets.

**Shares outstanding** as of March 31, 2026, were 252,884,261, excluding 6,143,226 shares held in treasury.

"Our revenues for the first quarter reflect the seasonal demand for COVID-19 vaccines and are in line with our expectations," **said Ramón Zapata, Chief Financial Officer at BioNTech**. "We are committed to a diligent capital allocation strategy that empowers us to pursue our goal of evolving into a leading biopharmaceutical company with multiple oncology products by 2030."

**Reaffirmed 2026 Financial Year Guidance**<sup>6</sup>**:**

---

| | |
|:---|:---|
| **Revenues for the 2026 financial year** | **€2,000 – €2,300 m** |

---

In 2026, BioNTech anticipates lower COVID-19 vaccine revenues compared to 2025, driven by declines in both the European and United States markets. The United States continues to be a competitive and dynamic market, where, as a result, lower revenues are expected. In Europe, the Company expects lower revenues as it defends its market share and begins managing the transition away from multi-year contracts. In Germany specifically, BioNTech recognizes direct sales of its COVID-19 vaccines as revenue. Hence, the anticipated declines in sales of COVID-19 vaccines in Germany will have a direct impact on the Company's topline, whereas revenues outside of Germany only affect the Company's topline as part of the 50% gross profit split with its partner Pfizer. Per the outlined partnership terms, revenues from the collaboration with Bristol Myers Squibb Company ("BMS") in 2026 are expected to be broadly in line with 2025. Revenues from the pandemic

------

![image_0a.jpg](image_0a.jpg)

preparedness contract with the German government and service businesses are expected to remain stable.

**Planned 2026 Financial Year Adjusted Expenses**<sup>6</sup>**:**

---

| | |
|:---|:---|
| **Adjusted R&D expenses** | **€2,200 – €2,500 m** |
| **Adjusted SG&A expenses**<sup>5</sup> | **€700 – €800 m** |

---

BioNTech will continue to focus investments on R&D and scaling the business for late-stage development and commercial readiness in oncology, while remaining cost-disciplined. Strategic capital allocation will continue to foster innovation and be a key driver of the Company's trajectory. As part of BioNTech's strategy, the Company may continue to evaluate appropriate corporate development opportunities with the aim of driving sustainable long-term growth and creating future value.

**Planned Capital Return to Shareholders**

The Management Board and Supervisory Board expect to authorize a share repurchase program of BioNTech's American Depositary Shares ("ADSs"), pursuant to which the Company may repurchase ADSs in the amount of up to $1.0 billion over the next twelve months. BioNTech expects to use the repurchased ADSs to satisfy obligations in the ordinary course of business. The program is designed to enhance capital efficiency and support long-term value creation to execute BioNTech's objective to become a multi-product company by 2030.

**Manufacturing Footprint Consolidation**

BioNTech continues to allocate capital strategically while optimizing capacities broadly to drive operational efficiency and sustainable value creation. To this end, BioNTech plans to align and consolidate its manufacturing network further where excess capacity is expected, due to evolving supply needs, mergers and acquisitions, BioNTech's partners' manufacturing capacities and completion of contracts.

BioNTech plans to exit operations at the manufacturing sites in Idar-Oberstein, Marburg, and Singapore as well as CureVac's sites, affecting up to approximately 1,860 positions in total. The exit from the sites in Idar-Oberstein, Marburg, and Tübingen is planned by the end of 2027, while operations in Singapore are expected to conclude in Q1 2027. For each of these manufacturing sites, BioNTech is exploring divestment options, including a partial or total sale.

BioNTech expects cost savings to ramp up over time, potentially reaching approximately €500 million in recurring annual savings upon full implementation of the measures in 2029.<sup>7</sup> These savings are intended to support the Company's capital allocation to further advance its growing oncology pipeline toward commercialization.

BioNTech continues to ensure a robust drug supply via its established manufacturing network. No impact on commercial or clinical supply nor contractual obligations is expected as the affected sites will become underutilized or idle in the next 24 months.

The full interim unaudited condensed consolidated financial statements can be found in BioNTech's Report on Form 6-K for the period ended March 31, 2026, filed today with the United States Securities and Exchange Commission ("SEC") and available at <u>www.sec.gov</u>.

**Endnotes**

<sup>1</sup> All numbers in this press release have been rounded.

<sup>2</sup> In addition to BioNTech's results determined in accordance with International Financial Reporting Standards ("IFRS"), or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures

------

![image_0a.jpg](image_0a.jpg)

used internally as a supplemental measure of the Company's business performance (each referred to with the prefix "Adjusted" or, as a whole, "Adjusted Results"). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech's measures based on IFRS Accounting Standards and more information can be found at the end of this press release and in BioNTech's Report on Form 6-K for the period ended March 31, 2026, filed on May 5, 2026, which is available at <u>www.sec.gov</u>. While non-IFRS measures may offer additional insights, BioNTech's non-IFRS measures are not, and should not be viewed as, a substitute for their most directly comparable IFRS Accounting Standards measures, and should always be considered alongside the Company's financial statements prepared in accordance with IFRS Accounting Standards.

<sup>3</sup> Calculated applying the average foreign exchange rate for the three months ended March 31, 2026, as published by the German Central Bank (Deutsche Bundesbank).

<sup>4</sup> As of March 31, 2026.

<sup>5</sup> Sales, general and administrative expenses ("SG&A") include sales and marketing expenses as well as general and administrative expenses. Adjusted SG&A expenses include adjusted sales and marketing expenses as well as adjusted general and administrative expenses.

<sup>6</sup> Excludes risks that are not yet known and/or quantifiable and related activities. Includes effects identified from licensing arrangements, collaborations and Merger & Acquisitions ("M&A") transactions to the extent disclosed. The guidance is based on non-IFRS measures and excludes certain effects compared to measures based on IFRS Accounting Standards. More information can be found in BioNTech's Report on Form 6-K for the period ended March 31, 2026, filed on May 5, 2026, which is available at <u>www.sec.gov</u>.

<sup>7</sup> Expected savings relative to BioNTech's 2025 cost base and CureVac's 2026 budget; do not reflect partially offsetting costs for Contract Development and Manufacturing Organizations ("CDMO") use or transfer to other sites; and exclude exit costs, which will be recorded as incurred.

<sup>8</sup> An overview of abbreviations of target structures and indications is compiled in a directory at the end of this press release.

***Select Oncology Pipeline Updates***

*Next-Generation Immunomodulators and Combinations*

**Pumitamig (BNT327/BMS986545)** is an investigational bispecific immunomodulator combining PD-L1<sup>8</sup> checkpoint inhibition with VEGF-A neutralization that is being developed in collaboration with BMS.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In the first quarter of 2026, the following pivotal trials evaluating pumitamig were initiated:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ A global Phase 3 clinical trial in patients with first-line triple-negative breast cancer ("TNBC") (ROSETTA Breast-01; <u>NCT07173751</u>).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ A global Phase 2/3 clinical trial in first-line microsatellite stable colorectal cancer ("MSS-CRC") (ROSETTA CRC-203; <u>NCT07221357</u>).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ A global Phase 2/3 clinical trial in first-line gastric cancer (ROSETTA Gastric-204; <u>NCT07221149</u>).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ A global Phase 3 clinical trial (ROSETTA Lung-201; <u>NCT07361497</u>) is being conducted to evaluate pumitamig compared to durvalumab following concurrent chemoradiation therapy in patients with unresectable stage III non-small cell lung cancer ("NSCLC").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ A global Phase 3 clinical trial (ROSETTA Lung-202; <u>NCT07361510</u>) is being conducted to evaluate pumitamig compared to pembrolizumab as a first-line treatment for patients with advanced PD-L1 ≥ 50% NSCLC.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A global Phase 2/3 clinical trial (ROSETTA Lung-02; <u>NCT06712316</u>) is ongoing to evaluate pumitamig in combination with chemotherapy compared to pembrolizumab and chemotherapy in patients with first-line NSCLC. The Phase 3 part of the trial is currently recruiting. Data from the Phase 2 part of the trial are expected at the American Society of Clinical Oncology ("ASCO") Annual Meeting 2026 (May 29 - June 2, 2026).

------

![image_0a.jpg](image_0a.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Pumitamig is also being evaluated in additional solid tumor indications, including first-line hepatocellular carcinoma ("HCC"), second-line glioblastoma ("GBM"), first-line pancreatic ductal adenocarcinoma ("PDAC") and first-line renal cell carcinoma ("RCC") in various Phase 1/2 and Phase 2 trials, both as monotherapy and in combination with standard of care.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• BioNTech has several signal-seeking clinical trials ongoing evaluating pumitamig with the Company's proprietary assets. These trials will inform the dose selection for pumitamig and explore anti-tumor activity in multiple tumors for later-stage development. Multiple data readouts from these combinations are expected in 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In April 2026, BioNTech and Boehringer Ingelheim announced a clinical trial collaboration to assess the safety, tolerability and early clinical activity of pumitamig in combination with obrixtamig (BI 764532), Boehringer Ingelheim's investigational DLL3/CD3 T-cell engager, in extensive-stage small cell lung cancer ("ES-SCLC"). Under the agreement, BioNTech will supply pumitamig and Boehringer Ingelheim will be the regulatory sponsor of the Phase 1b/2 trial.

**Gotistobart (BNT316/ONC-392)** is a tumor microenvironment-selective regulatory T cell depletion candidate that targets CTLA-4 and is being developed in collaboration with OncoC4, Inc. ("OncoC4").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A global Phase 3 clinical trial (PRESERVE-003; <u>NCT05671510</u>) is ongoing to evaluate the efficacy and safety of gotistobart as monotherapy in patients with metastatic squamous NSCLC that progressed under previous platinum-based chemotherapy and PD-(L)1-inhibitor treatment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In March 2026, updated data from the non-pivotal dose-confirmation stage, the first of two stages of the global Phase 3 clinical trial, were presented at the European Lung Cancer Congress ("ELCC"). Gotistobart demonstrated a clinically meaningful overall survival benefit compared to standard of care chemotherapy and a manageable safety profile in patients with squamous NSCLC whose disease had progressed following anti-PD-(L)1 therapy and platinum-based chemotherapy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Based on current event accrual projections, interim data from the pivotal stage of the two-stage Phase 3 clinical trial are expected in 2026.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In January 2026, gotistobart received Orphan Drug Designation from the U.S. Food and Drug Administration ("FDA") for the treatment of squamous NSCLC. In 2022, gotistobart received Fast Track Designation from the FDA for the treatment of patients with metastatic NSCLC whose disease progressed on prior anti-PD-(L)1 therapy.

*Antibody-Drug Conjugates*

**Trastuzumab pamirtecan** (BNT323/DB-1303) is an ADC candidate targeting HER2 that is being developed in collaboration with Duality Biologics (Suzhou) Co. Ltd. ("DualityBio").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A Phase 1/2 clinical trial (<u>NCT05150691</u>) is being conducted to evaluate trastuzumab pamirtecan in patients with advanced HER2-expressing tumors. A potentially registrational cohort with HER2-expressing (IHC3+, 2+, 1+ or ISH-positive) patients with recurrent endometrial cancer ("EC") is fully recruited.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In April 2026, updated data from this trial were presented at the Society of Gynecologic Oncology ("SGO") Annual Meeting. Trastuzumab pamirtecan demonstrated encouraging clinical efficacy across all HER2 expression levels and regardless of prior immunotherapy treatment. The safety profile in patients with pretreated advanced or metastatic EC was manageable and generally consistent with that of HER2-targeted biologics.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• BioNTech and DualityBio plan to file a biologics license application ("BLA") in 2026, subject to regulatory feedback.

------

![image_0a.jpg](image_0a.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A Phase 3 trial (FERN-EC-01, <u>NCT06340568</u>) is being conducted to evaluate trastuzumab pamirtecan compared to investigator's choice of chemotherapy in patients with advanced and HER2-expessing recurrent EC.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A global Phase 3 clinical trial (DYNASTY-Breast02, <u>NCT06018337</u>) to evaluate trastuzumab pamirtecan in patients with HR-positive, HER2-low metastatic breast cancer is ongoing. Based on current event accrual projections, data are expected in 2026.

**BNT324/DB-1311** is an ADC candidate targeting B7H3 that is being developed in collaboration with DualityBio.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In February 2026, updated data from a Phase 1/2 clinical trial (<u>NCT05914116</u>) were presented at the ASCO Genitourinary Cancers Symposium. BNT324/DB-1311 demonstrated durable efficacy in heavily pretreated metastatic castration-resistant prostate cancer ("mCRPC") patients with no new safety signals reported.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In April 2026, updated data from this trial were presented at the SGO Annual Meeting. BNT324/DB-1311 showed encouraging efficacy in previously treated cervical cancer and platinum resistant ovarian cancer ("PROC") particularly in patients with treatment-naïve cervical cancer. The safety profile in gynecologic malignancies was consistent with previous reports, and no new safety signals were observed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• A Phase 3 clinical trial (<u>NCT07365995</u>) to evaluate BNT324/DB-1311 compared to docetaxel in patients with mCRPC, is expected to initiate in 2026.

***Corporate and Commercial Update for the First Quarter 2026 and Post Period Events***

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• BioNTech and Pfizer developed, manufactured and delivered their variant-adapted COVID-19 vaccines, which have received multiple regulatory approvals, including full approvals, authorizations for emergency or temporary use or marketing authorizations, in more than 40 countries and regions. BioNTech is now focused on preparing for variant strain vaccine adaptation to be ready for commercial launch ahead of the upcoming 2026/2027 vaccination season, pending approvals.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In March 2026, BioNTech announced plans for an independent company to be established and led by BioNTech co-founders Prof. Ugur Sahin, M.D., and Prof. Özlem Türeci, M.D. The new company with distinct resources, operations and funding options will advance next-generation mRNA innovations. BioNTech plans to contribute related rights and mRNA technologies to the new company to enable and support the prioritized development of next-generation mRNA innovations with disruptive potential. With both companies focusing on their respective strategic priorities, BioNTech expects to maximize value for patients and shareholders alike. Ugur Sahin and Özlem Türeci will transition into the management of their new company by the end of 2026 after their current service agreements end. BioNTech's Supervisory Board has initiated an executive search to identify successors for the positions to ensure a smooth transition and seamless execution of BioNTech's strategy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• In March 2026, BioNTech published its Sustainability Report 2025. BioNTech recognizes the responsibility it has in how it is conducting its business and the impact its activities have on the economy, people, and the environment. The Sustainability Report 2025 outlines BioNTech's efforts, progress, key initiatives, and data as well as highlights in its corporate sustainability and responsibility over the past year.

**Upcoming Investor and Analyst Events**

• BioNTech Annual General Meeting: May 15, 2026

• BioNTech Second Quarter 2026 Financial Results and Corporate Update: August 4, 2026

------

![image_0a.jpg](image_0a.jpg)

**Conference Call and Webcast Information**

BioNTech invites investors and the general public to join a conference call and webcast with investment analysts today, May 5, 2026, at 8:00 a.m. ET (2:00 p.m. CET) to report its financial results and provide a corporate update for the first quarter of 2026.

To access the live conference call via telephone, please register <u>via this link</u>. Once registered, dial-in numbers and a PIN number will be provided.

The slide presentation and audio of the webcast will be available <u>via this link</u>.

Participants may also access the slides and the webcast of the conference call via the "Events & Presentations" page of the Investor section of the Company's website at <u>www.BioNTech.com</u>. A replay of the webcast will be made available shortly after the closing of the call and archived on the Company's website for 30 days following the call.

**About BioNTech**

BioNTech is a global next generation biopharmaceutical company pioneering novel investigative therapies for cancer and other serious diseases. In oncology, BioNTech is committed to transforming how cancer is treated. Its ambition is to develop innovative medicines with pan-tumor or synergistic potential to address cancer from multiple angles and across the full continuum of the disease from early- to late-stage. Its growing late-stage oncology pipeline comprises complementary treatment approaches spanning immunomodulators, antibody drug conjugates, and mRNA cancer immunotherapies. BioNTech has partnered with multiple global and specialized pharmaceutical collaborators leveraging complementary expertise and resources to accelerate innovation and drive progress, including Bristol Myers Squibb, Duality Biologics, Genentech, a member of the Roche Group, Genmab, MediLink, OncoC4, and Pfizer.

For more information, please visit <u>www.BioNTech.com</u>.

**Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: expected changes to BioNTech's leadership and the transition of responsibilities at the Management Board, including identification and recruitment of successors; the terms of the preliminary discussions between BioNTech and the co-founders regarding the potential contribution of certain BioNTech assets to an independent company; BioNTech's expected revenues and net profit/(loss) related to sales of BioNTech's COVID-19 vaccine in territories controlled by BioNTech's collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech's partners; the rate and degree of market acceptance of BioNTech's COVID-19 vaccine and, if approved, BioNTech's investigational medicines; expectations regarding anticipated changes in COVID-19 vaccine demand, including changes to the ordering environment and expected regulatory recommendations to adapt vaccines to address new variants or sublineages; the initiation, timing, progress, results, and cost of BioNTech's research and development programs, including BioNTech's current and future preclinical studies and clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of studies or clinical trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations; BioNTech's expectations regarding potential future commercialization in oncology, including goals regarding timing and indications; the targeted timing and number of additional potentially registrational clinical trials, and the registrational potential of any clinical trial BioNTech may initiate; BioNTech's expectations regarding the impact of changes to its manufacturing operations; discussions with regulatory agencies; BioNTech's expectations with respect to intellectual property; the impact of BioNTech's collaboration and licensing agreements, including BioNTech's

------

![image_0a.jpg](image_0a.jpg)

partnership with Bristol Myers Squibb; BioNTech's expectations with respect to developments in law, public policy, and international trade; BioNTech's estimates of revenues, research and development expenses, selling, general and administrative expenses and capital expenditures for operating activities; BioNTech's expectations for upcoming scientific and investor presentations; and BioNTech's expectations of net profit/(loss). In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words.

The forward-looking statements in this press release are based on BioNTech's current expectations and beliefs of future events, and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech's control and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, projected data release timelines, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this release, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; BioNTech's pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors; the future commercial demand and medical need for initial or annual booster doses of a COVID-19 vaccine; the impact of tariffs and escalations in trade policy; competition from other COVID-19 vaccines or related to BioNTech's other product candidates; the timing of and BioNTech's ability to obtain and maintain regulatory approval for its product candidates; the ability of BioNTech's COVID-19 vaccines to prevent COVID-19 caused by emerging virus variants; BioNTech's ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech's third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech's and its collaborators' ability to commercialize and market its product candidates, if approved; BioNTech's ability to manage its development and related expenses; regulatory and political developments; BioNTech's ability to effectively scale its production capabilities and manufacture its products and product candidates; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time.

You should review the risks and uncertainties described under the heading "Risk Factors" in BioNTech's Report on Form 6-K for the period ended March 31, 2026 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC's website at <u>www.sec.gov</u>. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.

------

![image_0a.jpg](image_0a.jpg)

**CONTACTS**

**Investor Relations**

Douglas Maffei, PhD

<u>Investors@biontech.de</u> 

**Media Relations**<br> Jasmina Alatovic<br><u>Media@biontech.de</u>

------

![image_0a.jpg](image_0a.jpg)

**Abbreviation Overview**

---

| | |
|:---|:---|
| 1L | First line |
| 2L | Second line |
| ADC | Antibody-drug conjugate |
| B7H3 | Also known as CD276, cluster of differentiation 276 |
| BLA | Biologics license application |
| CTLA-4 | Cytotoxic T-lymphocyte-associated protein |
| EC | Endometrial cancer |
| ES-SCLC | Extensive-stage small cell lung cancer |
| GBM | Glioblastoma |
| HCC | Hepatocellular carcinoma |
| HER2 (or HER3) | Human epidermal growth factor receptor 2 (or 3) |
| HPV16 | Human papilloma virus 16 |
| HR | Hormone receptor |
| IHC3+, 2+, 1+ | Immunohistochemistry score 1+ (or 2+ or 3+) |
| IO | Immuno-oncology |
| ISH-positive | *In-situ* hybridization positive |
| mCRPC | Metastatic castration-resistant prostate cancer |
| MSS-CRC | Microsatellite stable colorectal cancer |
| NSCLC | Non-small cell lung cancer |
| PDAC | Pancreatic ductal adenocarcinoma |
| PD-(L)1 | Programmed cell death protein (death-ligand) 1 |
| PROC | Platinum resistant ovarian cancer |
| RCC | Renal cell carcinoma |
| SCLC | Small cell lung cancer |
| TNBC | Triple-negative breast cancer |
| TROP2 | Trophoblast cell-surface antigen 2 |
| VEGF-A | Vascular endothelial growth factor A |

---

------

![image_0a.jpg](image_0a.jpg)

**Interim Condensed Consolidated Statements of Profit or Loss**

---

| | | |
|:---|:---|:---|
| | **Three months ended March 31,** | **Three months ended March 31,** |
| | **2026** | **2025** |
| <br><br>*(in millions €, except per share data)* | *(unaudited)* | *(unaudited)* |
| Revenues | 118.1 | 182.8 |
| Cost of sales | (71.4) | (83.8) |
| Research and development expenses | (557.0) | (525.6) |
| Sales and marketing expenses | (27.9) | (13.7) |
| General and administrative expenses | (122.9) | (106.9) |
| Other operating expenses | (46.8) | (48.5) |
| Other operating income | 30.4 | 61.6 |
| **Operating loss** | **(677.5)** | **(534.1)** |
| Finance income | 120.6 | 122.6 |
| Finance expenses | (11.2) | (33.9) |
| **Loss before tax** | **(568.1)** | **(445.4)** |
| Income taxes | 36.2 | 29.6 |
| **Net loss** | **(531.9)** | **(415.8)** |
| **Loss per share** |  |  |
| Basic and diluted loss per share | (2.10) | (1.73) |

---

------

![image_0a.jpg](image_0a.jpg)

**Interim Condensed Consolidated Statements of Profit or Loss <br>(Adjusted Results)**

---

| | | |
|:---|:---|:---|
| **Adjusted Results (non-IFRS measures)**<sup>1</sup> | **Three months ended March 31,** | **Three months ended March 31,** |
|  | **2026** | **2025** |
| *(in millions €, except per share data)* | *(unaudited)* | *(unaudited)* |
| Adjusted research and development expenses | (527.1) | (525.6) |
| Adjusted other operating expenses | (39.4) | (48.5) |
| Adjusted other operating income | 30.4 | 46.6 |
| **Adjusted operating loss** | **(640.2)** | **(549.1)** |
| **Adjusted loss before tax** | **(530.8)** | **(460.4)** |
| **Adjusted net loss**<sup>2</sup> | **(494.6)** | **(430.8)** |
| **Adjusted loss per share** |  |  |
| Adjusted basic and diluted loss per share | (1.95) | (1.79) |

---

<sup>1</sup> Certain adjusted results presented in this table are identical to BioNTech's results under IFRS Accounting Standards. Reconciliation of all other adjusted results to the Company's IFRS results can be found at the end of this press release and in BioNTech's Report on Form 6-K for the period ended March 31, 2026 filed on May 5, 2026, which is available at <u>www.sec.gov</u>.

<sup>2</sup> Tax effects are not considered as part of our non-IFRS adjustments.

------

![image_0a.jpg](image_0a.jpg)

**Interim Condensed Consolidated Statements of Financial Position**

---

| | | |
|:---|:---|:---|
|  | **March 31** | **December 31,** |
| *(in millions €)* | **2026** | **2025** |
| **Assets**  | *(unaudited)* |  |
| **Non-current assets**  |  |  |
| Goodwill | 370.5 | 367.9 |
| Other intangible assets  | 1546.8 | 1606.0 |
| Property, plant and equipment  | 1112.7 | 1080.9 |
| Right-of-use assets | 205.5 | 210.2 |
| Contract assets  |  | 2.0 |
| Other financial assets | 2279.9 | 2554.2 |
| Other non-financial assets | 12.2 | 7.3 |
| Deferred tax assets  | 14.7 | 13.5 |
| **Total non-current assets**  | **5542.3** | **5842.0** |
| **Current assets** |  |  |
| Inventories  | 103.8 | 110.7 |
| Trade and other receivables  | 539.2 | 924.2 |
| Contract assets  | 8.9 | 8.1 |
| Other financial assets  | 4699.8 | 7201.8 |
| Other non-financial assets | 176.6 | 173.8 |
| Income tax assets  | 64.1 | 52.6 |
| Cash and cash equivalents | 9939.4 | 7675.4 |
| **Total current assets**  | **15531.8** | **16146.6** |
| **Total assets** | **21074.1** | **21988.6** |
| **Equity and liabilities**  |  |  |
| **Equity**  |  |  |
| Share capital | 259.0 | 259.0 |
| Capital reserve | 2468.2 | 2473.3 |
| Treasury shares | (6.1) | (7.7) |
| Retained earnings | 17430.0 | 17961.9 |
| Other reserves  | (1453.3) | (1462.3) |
| **Total equity**  | **18697.8** | **19224.2** |
| **Non-current liabilities**  |  |  |
| Lease liabilities, loans and borrowings | 246.1 | 215.2 |
| Other financial liabilities  | 92.0 | 94.9 |
| Provisions | 23.8 | 35.5 |
| Contract liabilities | 87.7 | 88.0 |
| Other non-financial liabilities | 108.8 | 104.2 |
| Deferred tax liabilities | 52.9 | 84.3 |
| **Total non-current liabilities**  | **611.3** | **622.1** |
| **Current liabilities**  |  |  |
| Lease liabilities, loans and borrowings | 56.7 | 52.2 |
| Trade payables and other payables | 468.8 | 534.9 |
| Other financial liabilities  | 77.5 | 351.7 |
| Income tax liabilities | 38.1 | 65.6 |
| Provisions | 167.0 | 145.3 |
| Contract liabilities | 758.5 | 754.9 |
| Other non-financial liabilities | 198.4 | 237.7 |
| **Total current liabilities** | **1765.0** | **2142.3** |
| **Total liabilities**  | **2376.3** | **2764.4** |
| **Total equity and liabilities**  | **21074.1** | **21988.6** |

---

------

![image_0a.jpg](image_0a.jpg)

**Interim Condensed Consolidated Statements of Cash Flows**

---

| | | |
|:---|:---|:---|
| | **Three months ended March 31,** | **Three months ended March 31,** |
| | **2026** | **2025** |
| <br><br>*(in millions €)* | *(unaudited)* | *(unaudited)* |
| **Operating activities** |  |  |
| Net loss | (531.9) | (415.8) |
| Income taxes | (36.2) | (29.6) |
| **Loss before tax** | **(568.1)** | **(445.4)** |
| **Adjustments to reconcile loss before tax to net cash flows:**  |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation, amortization and impairment of property, plant, equipment, intangible assets and right-of-use assets | 121.3 | 42.8 |
| &nbsp;&nbsp;&nbsp;Share-based payment expenses | 22.8 | 22.1 |
| &nbsp;&nbsp;&nbsp;Net foreign exchange differences | 0.4 | 48.3 |
| &nbsp;&nbsp;&nbsp;Gain on disposal of property, plant and equipment | (0.1) | (0.1) |
| &nbsp;&nbsp;&nbsp;Finance income excluding foreign exchange differences | (111.0) | (122.6) |
| &nbsp;&nbsp;&nbsp;Finance expense excluding foreign exchange differences | 11.2 | 7.9 |
| &nbsp;&nbsp;&nbsp;Government and similar grants | (17.6) | (14.5) |
| &nbsp;&nbsp;&nbsp;Other non-cash income |  | (15.0) |
| **Working capital adjustments:** |  |  |
| &nbsp;&nbsp;&nbsp;Decrease in trade and other receivables, contract assets and other assets | 431.1 | 520.7 |
| &nbsp;&nbsp;&nbsp;Decrease in inventories | 7.0 | 33.8 |
| &nbsp;&nbsp;&nbsp;Decrease in trade payables, other financial liabilities, other liabilities, contract liabilities, refund liabilities and provisions | (371.9) | (981.6) |
| Interest received and realized gains from cash and cash equivalents | 86.6 | 118.6 |
| Interest paid and realized losses from cash and cash equivalents | (3.3) | (3.1) |
| Income tax paid, net | (41.6) | (12.2) |
| Share-based payments | (2.1) | (3.6) |
| Government and similar grants received | 14.3 | 23.2 |
| **Net cash flows used in operating activities** | **(421.0)** | **(780.7)** |
| **Investing activities** |  |  |
| Purchase of property, plant and equipment | (56.8) | (48.9) |
| Proceeds from sale of property, plant and equipment | 1.6 | 0.5 |
| Purchase of intangible assets | (22.1) | (569.2) |
| Acquisition of subsidiaries and businesses, net of cash acquired |  | (78.5) |
| Investment in other financial assets | (1550.2) | (2507.7) |
| Proceeds from maturity of other financial assets | 4278.1 | 4450.6 |
| **Net cash flows from investing activities** | **2650.6** | **1246.8** |
| **Financing activities** |  |  |
| Proceeds from loans and borrowings | 38.4 |  |
| Repayment of loans and borrowings | (0.1) | (4.5) |
| Payments related to lease liabilities | (11.9) | (9.3) |
| **Net cash flows from / (used in) financing activities** | **26.4** | **(13.8)** |
| Net increase in cash and cash equivalents | 2256.0 | 452.3 |
| Change in cash and cash equivalents resulting from exchange rate differences | (3.4) | (16.1) |
| Change in cash and cash equivalents resulting from other valuation effects | 11.4 | (13.2) |
| Cash and cash equivalents at the beginning of the period | 7675.4 | 9761.9 |
| **Cash and cash equivalents as of March 31** | **9939.4** | **10184.9** |

---

Certain prior period lines were aggregated to conform to current period presentation.

------

![image_0a.jpg](image_0a.jpg)

**Non-IFRS Reconciliation**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Non-IFRS Reconciliation for the three months ended March 31, 2026** | **Non-IFRS Reconciliation for the three months ended March 31, 2026** | **Non-IFRS Reconciliation for the three months ended March 31, 2026** | **Non-IFRS Reconciliation for the three months ended March 31, 2026** | **Non-IFRS Reconciliation for the three months ended March 31, 2026** | **Non-IFRS Reconciliation for the three months ended March 31, 2026** | **Non-IFRS Reconciliation for the three months ended March 31, 2026** |
|  |  | **non-IFRS adjustments (unaudited)** | **non-IFRS adjustments (unaudited)** | **non-IFRS adjustments (unaudited)** | **non-IFRS adjustments (unaudited)** |  |
| *(in millions €, except per share data)* | **IFRS** <br>**Results** | **Expenses and income from legal proceedings** | **Impairment and reversal** | **Employee-related expenses from restructuring** | **Income from bargain purchase and income and expenses from divestiture related items** | **Adjusted** <br>**Results** |
| *(in millions €, except per share data)* | *(unaudited)* | **Expenses and income from legal proceedings** | **Impairment and reversal** | **Employee-related expenses from restructuring** | **Income from bargain purchase and income and expenses from divestiture related items** | *(unaudited)* |
| Research and development expenses | (557.0) |  | 29.9 |  |  | (527.1) |
| Other operating expenses | (46.8) |  |  | 7.4 |  | (39.4) |
| **Operating loss** | **(677.5)** | **—** | **29.9** | **7.4** | **—** | **(640.2)** |
| **Loss before tax** | **(568.1)** | **—** | **29.9** | **7.4** | **—** | **(530.8)** |
| **Net loss**<sup>1</sup> | **(531.9)** | **—** | **29.9** | **7.4** | **—** | **(494.6)** |
| **Loss per share** |  |  |  |  |  |  |
| Basic and diluted loss per share | (2.10) |  |  |  |  | (1.95) |

---

<sup>1</sup> Tax effects are not considered as part of BioNTech's non-IFRS adjustments.

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| **Non-IFRS Reconciliation for the three months ended March 31, 2025** | **Non-IFRS Reconciliation for the three months ended March 31, 2025** | **Non-IFRS Reconciliation for the three months ended March 31, 2025** | **Non-IFRS Reconciliation for the three months ended March 31, 2025** | **Non-IFRS Reconciliation for the three months ended March 31, 2025** | **Non-IFRS Reconciliation for the three months ended March 31, 2025** | **Non-IFRS Reconciliation for the three months ended March 31, 2025** |
|  |  | **non-IFRS adjustments (unaudited)** | **non-IFRS adjustments (unaudited)** | **non-IFRS adjustments (unaudited)** | **non-IFRS adjustments (unaudited)** |  |
| *(in millions €, except per share data)* | **IFRS** <br>**Results** | **Expenses and income from legal proceedings** | **Impairment and reversal** | **Employee-related expenses from restructuring** | **Income from bargain purchase and income and expenses from divestiture related items** | **Adjusted** <br>**Results** |
| *(in millions €, except per share data)* | *(unaudited)* | **Expenses and income from legal proceedings** | **Impairment and reversal** | **Employee-related expenses from restructuring** | **Income from bargain purchase and income and expenses from divestiture related items** | *(unaudited)* |
| Other operating income | 61.6 |  |  |  | (15.0) | 46.6 |
| **Operating loss** | **(534.1)** | **—** | **—** | **—** | **(15.0)** | **(549.1)** |
| **Loss before tax** | **(445.4)** | **—** | **—** | **—** | **(15.0)** | **(460.4)** |
| **Net loss**<sup>1</sup> | **(415.8)** | **—** | **—** | **—** | **(15.0)** | **(430.8)** |
| **Loss per share** |  |  |  |  |  |  |
| Basic and diluted loss per share | (1.73) |  |  |  |  | (1.79) |

---

<sup>1</sup> Tax effects are not considered as part of BioNTech's non-IFRS adjustments.

## Exhibit 99.2

![](a992bntx1q2026presentati001.jpg)

First Quarter 2026 Financial Results & Corporate Update May 5, 2026 Exhibit 99.2

------

![](a992bntx1q2026presentati002.jpg)

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech's expected revenues and net profit/(loss) related to sales of BioNTech's COVID-19 vaccine, referred to as COMIRNATY where approved for use under full or conditional marketing authorization, in territories controlled by BioNTech's collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech's partners; the rate and degree of market acceptance of BioNTech's COVID-19 vaccine and, if approved, BioNTech's investigational medicines; expectations regarding anticipated changes in COVID-19 vaccine demand; the initiation, timing, progress, results, and cost of BioNTech's research and development programs, including BioNTech's current and future preclinical studies and clinical trials, including statements regarding the expected timing of initiation, enrollment, and completion of studies or trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations; BioNTech's expectations regarding potential future commercialization in oncology, including goals regarding timing and indications; the targeted timing and number of additional potentially registrational trials, and the registrational potential of any trial BioNTech may initiate; BioNTech's expectations regarding the impact of changes to its manufacturing operations; discussions with regulatory agencies; BioNTech's expectations with respect to intellectual property; the impact of BioNTech's collaboration and licensing agreements, including BioNTech's partnership with BMS; BioNTech's expectations with respect to developments in law, public policy, and international trade; BioNTech's estimates of revenues, research and development expenses, selling, general and administrative expenses, and capital expenditures for operating activities; BioNTech's expectations for upcoming scientific and investor presentations; and BioNTech's expectations of net profit/(loss). In some cases, forward-looking statements can be identified by terminology such as "will," "may," "should," "expects," "intends," "plans," "aims," "anticipates," "believes," "estimates," "predicts," "potential," "continue," or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are based on BioNTech's current expectations and beliefs of future events and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech's control, and which could cause actual results to differ materially and adversely from those expressed or implied by these forward- looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, projected data release timelines, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this presentation, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; BioNTech's pricing and coverage negotiations with governmental authorities, private health insurers and other third-party payors; the future commercial demand and medical need for initial or booster doses of a COVID-19 vaccine; the impact of tariffs and escalations in trade policy; competition from other COVID-19 vaccines or related to BioNTech's other product candidates; the timing of and BioNTech's ability to obtain and maintain regulatory approval for its product candidates; the ability of BioNTech's COVID-19 vaccines to prevent COVID-19 caused by emerging virus variants; BioNTech's ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech's third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech's and its collaborators' ability to commercialize and market its product candidates, if approved; BioNTech's ability to manage its development and related expenses; regulatory and political developments in the United States and other countries; BioNTech's ability to effectively scale its production capabilities and manufacture its products and product candidates; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time. You should review the risks and uncertainties described under the heading "Risk Factors" in BioNTech's Report on Form 6-K for the period ended March 31, 2026, and in subsequent filings made by BioNTech with the SEC, which are available on the SEC's website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise. Furthermore, certain statements contained in this presentation relate to or are based on studies, publications, surveys and other data obtained from third-party sources and BioNTech's own internal estimates and research. While BioNTech believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, any market data included in this presentation involves assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. While BioNTech believes its own internal research is reliable, such research has not been verified by any independent source. In addition, BioNTech is the owner of various trademarks, trade names and service marks that may appear in this presentation. Certain other trademarks, trade names and service marks appearing in this presentation are the property of third parties. Solely for convenience, the trademarks and trade names in this presentation may be referred to without the® and TM symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. 2 An abbreviation directory of defined terms can be found at the end of the presentation. To be updated by Legal This Slide Presentation Includes Forward-Looking Statements

------

![](a992bntx1q2026presentati003.jpg)

1 Progress Highlights Prof. Uğur Şahin, M.D., Co-Founder & Chief Executive Officer 2 Oncology Execution Prof. Özlem Türeci, M.D., Co-Founder & Chief Medical Officer 3 Financial Performance Ramón Zapata, Chief Financial Officer

------

![](a992bntx1q2026presentati004.jpg)

Progress Highlights Prof. Uğur Şahin, M.D., Co-Founder & Chief Executive Officer 1 4

------

![](a992bntx1q2026presentati005.jpg)

Modalities to Disease Areas Transition to a focused disease area specific approach Late-Stage Acceleration Key late-stage data readouts expected for first wave of oncology assets Oncology Focus in 2026 Combination Therapy Momentum Novel-novel pumitamig1 combination data readouts expected 1 2 3 1. Partnered with Bristol Myers Squibb 5

------

![](a992bntx1q2026presentati006.jpg)

Building a Multi-Product Company by 2030 Targeting 17+ Late-Stage/Pivotal Trial Readouts Through 2030+ Informing Multiple Launch Opportunities 6 Tumor Type Incidence1 Assets Late-Stage/Pivotal Trials Expected Data Readouts2 2026 2027 2028 2029 2030+ Lung 1L NSCLC 400K Pumitamig3 ROSETTA Lung-02 Stage III unresectable NSCLC 65K Pumitamig3 ROSETTA Lung-201 1L NSCLC – PD-L1 ≥ 50% 60K Pumitamig3 ROSETTA Lung-202 2L+ sqNSCLC1 55K Gotistobart4 PRESERVE-003 1L ES-SCLC 80k Pumitamig3 ROSETTA Lung-01 Breast 1L TNBC – all comers 20k Pumitamig3 Phase 3 in China 1L TNBC – CPS < 10 15k Pumitamig3 ROSETTA Breast-01 2L+ HR+ BC1 – HER2-low 55k Trastuzumab pamirtecan5 DYNASTY Breast-02 Genitourinary 1L RCC 40k Pumitamig3 ROSETTA RCC-2087 1L CRPC 110k BNT324/DB-13115 BNT324-03 Gastrointestinal 1L MSS-CRC 230k Pumitamig3 ROSETTA CRC-203 1L Gastric – HER2-neg, PD-L1+ 40k Pumitamig3 ROSETTA Gastric-204 1L HCC 25k Pumitamig3 ROSETTA HCC-2067 Adj. CRC - ctDNA+ 70k Autogene cevumeran6 BNT122-01 Adj. PDAC 30k Autogene cevumeran6 IMCODE003 Gynecologic 2L+ Endometrial1 – HER2-expressing 10k Trastuzumab pamirtecan5 Single-arm Phase 2 Trastuzumab pamirtecan5 Fern-EC-01 Additional Tumors 1L HNSCC – PD-L1 CPS ≥ 1, HPV16+ 50k BNT113 AHEAD-MERIT 1. Estimated 1L or adjuvant incidence (incidence + newly recurrent patients), or 2L+ drug-treated in 2030 in the G7 markets derived from Oracle CancerMPact as of Feb 2026; Incidence information is for informational purposes only and is not intended to indicate the potential market size or reach of BioNTech's and its collaborators' product candidates, if approved. 2. Expected data readouts may be from interim or final analyses and are event-driven, and in some cases may not translate into commercial launches; Partnered with 3. Bristol Myers Squibb; 4. OncoC4; 5. DualityBio; 6. Genentech, a member of the Roche group; 7. These are Phase 1/2 trials. The anticipated pivotal trials evaluating pumitamig in these tumor types are expected to readout after 2030.

------

![](a992bntx1q2026presentati007.jpg)

Oncology Execution Prof. Özlem Türeci, M.D., Co-Founder & Chief Medical Officer 2 7

------

![](a992bntx1q2026presentati008.jpg)

BioNTech Key Tumor Focus Areas to Address Significant Unmet Medical Needs Lung Breast Genitourinary Gastrointestinal Gynecologic Additional Tumors Pumitamig1 ADC IO mRNA 1. Partnered with Bristol Myers Squibb Leveraging novel combinations to maximize pipeline potential and elevate solid tumor treatment outcomes 8

------

![](a992bntx1q2026presentati009.jpg)

1L metastatic 2L+ metastatic 80K 35K Resectable Stage III Unresectable 1L metastatic 2L+ metastatic Incidence1 220K 65K 400K 230K Broadening BioNTech's Coverage of Lung Cancer to Maximize Pipeline Potential 9 1. Estimated 1L or adjuvant incidence (incidence + newly recurrent patients), or 2L+ drug-treated in 2030 in the G7 markets derived from Oracle CancerMPact as of Feb 2026; Incidence information is for informational purposes only and is not intended to indicate the potential market size or reach of BioNTech's and its collaborators' product candidates, if approved; Partnered with: 2. Bristol Myers Squibb; 3. OncoC4; 4. DualityBio (BNT324/DB-1311, Sacituzumab drozuntecan (formerly BNT325-DB1305)); 5. MediLink (BNT326/YL202), 6. being conducted in China. Next generation IO Targeted therapy mRNA immunotherapy Registrational trials Ph1/2 PoC trials NSCLC SCLC Gotistobart3 PRESERVE-003 (sq) FixVac + Gotistobart3/ADCs LuCa-MERIT-1 Pumitamig2 + chemo IIT6 Pumitamig2 + chemo ROSETTA LUNG-02 ADC monos BNT3244, Sacituzumab drozuntecan4, BNT3265 Pumitamig2 + ADCs BNT3244, Sacituzumab drozuntecan4, BNT3265 Pumitamig2 ROSETTA LUNG-201 Pumitamig2 + FixVac LuCa-MERIT-1 Pumitamig2 ROSETTA LUNG-202 Pumitamig2 + chemo ROSETTA LUNG-01 Pumitamig2 + ADC (BNT3244) ADC mono BNT3244 Pumitamig2 + TCE

------

![](a992bntx1q2026presentati010.jpg)

Median PFS Median OS Pumitamig Data Show Preliminary Antitumor Activity Irrespective of PD-L1 Expression in NSCLC Phase 1/2 Trial in China Monotherapy Data at ELCC 2026 in Squamous and Non-squamous NSCLC across PD-L1 Expression Median PFS, months (95% CI) Overall NSQ and SQ (N = 30) 13.6 (8.3–NR) Median OS, months (95% CI) Overall NSQ and SQ (N = 30) 27.0 (13.9–NR) No. of patients at risk 30 22 22 17 7 6 4 3 3 3 2 1 Overall (NSQ & SQ) P F S (%) Months 0 3 6 9 12 15 18 21 24 27 30 33 36 0 20 40 60 80 100 No. of patients at risk 30 29 27 26 13 10 7 6 6 6 4 4 0 Overall (NSQ & SQ) • Encouraging antitumor activity in patients with previously untreated ad- vanced NSCLC PD-L1 ≥1%, including those with squamous cell carcinoma • Manageable safety & tolerability, with a low rate of treatment discontinuation • Pumitamig monotherapy and in combination with chemotherapy for NSCLC is being further investigated in ongoing global studies Key Findings Zhang, et al. ELCC 2026 69P Global Phase 2 pumitamig + chemotherapy data in 1L NSCLC expected at ASCO 10 O S (%) Months 0 3 6 9 12 15 18 21 24 27 30 33 36 0 20 40 60 80 100 Patient Population Overall (n=30) NSQ NSCLC SQ NSCLC PD-L1 1%-49% (n=9) PD-L1 ≥50% (n=8) PD-L1 1%-49% (n=6) PD-L1 ≥50% (n=7) cORR, % (95% CI) 46.7 (28.3–65.7) 44.4 (13.7–78.8) 37.5 (8.5–75.5) 33.3 (4.3–77.7) 71.4 (29.0–96.3) DCR, % (95% CI) 96.7 (82.8–99.9) 100 (66.4–100) 100 (63.1–100) 83.3 (35.9–99.6) 100 (59.0–100)

------

![](a992bntx1q2026presentati011.jpg)

1L metastatic 2L+ metastatic 80K 35K Resectable Stage III Unresectable 1L metastatic 2L+ metastatic Incidence1 220K 65K 400K 230K Broadening BioNTech's Coverage of Lung Cancer to Maximize Pipeline Potential 11 1. Estimated 1L or adjuvant incidence (incidence + newly recurrent patients), or 2L+ drug-treated in 2030 in the G7 markets derived from Oracle CancerMPact as of Feb 2026; Incidence information is for informational purposes only and is not intended to indicate the potential market size or reach of BioNTech's and its collaborators' product candidates, if approved; Partnered with: 2. Bristol Myers Squibb; 3. OncoC4; 4. DualityBio (BNT324/DB-1311, Sacituzumab drozuntecan (formerly BNT325-DB1305)); 5. MediLink (BNT326/YL202), 6. being conducted in China. Next generation IO Targeted therapy mRNA immunotherapy Registrational trials Ph1/2 PoC trials NSCLC SCLC Gotistobart3 PRESERVE-003 (sq) FixVac + Gotistobart3/ADCs LuCa-MERIT-1 Pumitamig2 + chemo IIT6 Pumitamig2 + chemo ROSETTA LUNG-02 ADC monos BNT3244, Sacituzumab drozuntecan4, BNT3265 Pumitamig2 + ADCs BNT3244, Sacituzumab drozuntecan4, BNT3265 Pumitamig2 ROSETTA LUNG-201 Pumitamig2 + FixVac LuCa-MERIT-1 Pumitamig2 ROSETTA LUNG-202 Pumitamig2 + chemo ROSETTA LUNG-01 Pumitamig2 + ADC (BNT3244) ADC mono BNT3244 Pumitamig2 + TCE

------

![](a992bntx1q2026presentati012.jpg)

Docetaxel 30.3 (16.2–45.6) 0 10 20 30 40 50 60 70 80 90 100 Gotistobart 63.1 (46.9–75.5) 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 Gotistobart Phase 3 Data Show Survival Benefit in CPI-Treated Squamous NSCLC 12 1. Partnered with OncoC4; 2. Not from formal hypothesis; 3.Calculated based on reversed Kaplan–Meier method with OS event as 0 (censored) and the last follow-up date or withdrawal date as event. Gotistobart (n=45) Docetaxel (n=42) Median OS, months (95% CI) NE (9.33–NE) 9.95 (6.18–11.93) ORR, n (%) 9 (20.0) 2 (4.8) Median PFS, months (95% CI) 2.4 (2.1, 4.5) 2.6 (2.1, 3.9) 12-month PFS rate, % 25.2 0 Median duration of follow-up, months (Q1, Q3) 3 14.5 (13.0, 16.4) 15.2 (11.5, 16.0) HR (95% CI): 0.46 (0.25–0.84) Nominal p=0.01022 Kai He, et al. ELCC 2026 FPN 3O Overall safety profile aligns with previously established safety profile PRESERVE-003 trial stage 1 data at ELCC 2026: gotistobart1 reduces risk of death by 54% compared with docetaxel Interim data from pivotal stage of Phase 3 trial expected in 2026 Overall Survival O v e ra ll s u rv iv a l (%) Time from randomization (months)

------

![](a992bntx1q2026presentati013.jpg)

BioNTech Key Tumor Focus Areas to Address Significant Unmet Medical Needs Lung Breast Genitourinary Gastrointestinal Gynecologic Additional Tumors Pumitamig1 ADC IO mRNA 1. Partnered with Bristol Myers Squibb Leveraging novel combinations to maximize pipeline potential and elevate solid tumor treatment outcomes 13

------

![](a992bntx1q2026presentati014.jpg)

14 Trastuzumab Pamirtecan: Encouraging Data in HER2-expressing EC Patient Population HER2-expressing (Central Testing) Prior ICI (n=73) All Patients (n=96) Confirmed ORR,3 % (95% CI) 49.3 (37.4, 61.3) 47.9 (37.6, 58.4) Median DoR,3 months (95% CI) 9.9 (7.0, NE) 11.1 (9.0, 18.3) DCR,3,4 % (95% CI) 79.5 (68.4, 88.0) 83.3 (74.4, 90.2) Median PFS,5 months (95% CI) (n=74) 6.8 (5.4, 11.0) (n=97) 8.1 (5.5, 11.8) Efficacy Measures C o n fi rm e d O R R , % (9 5 % C I) 0 20 40 60 80 100 34.5 (17.9, 54.3)33.9 (22.1, 47.4) 44.2 (29.1, 60.1) 40.4 (27.6, 54.2) 70.8 (48.9, 87.4) 73.1 (52.2, 88.4) HER2 IHC 1+ HER2 IHC 2+ HER2 IHC 3+ • 49.3% confirmed ORR by IRC in patients with prior ICI treatment and central testing for HER2-expression • Responses were observed across all HER2 expression levels (IHC 1+, 2+ or 3+) • Efficacy was consistent regardless of HER2 status by central or local testing • Manageable safety profile Key Findings Data in Phase 1/2, Open-label, Dose-escalation and Expansion Study in HER2-expressing EC Confirmed Objective Response Rate by HER2 IHC Score1 n=59 n=57 n=26n=29 n=43 n=24 Central testing (N=96) Local testing (N=142)2 Pothuri, et al. SGO 2026 1. By IRC in the modified FAS, which includes patients who received ≥1 dose of trastuzumab pamirtecan and had at least one measurable lesion as assessed by IRC at baseline according to RECIST v1.1; 2. IHC score was not available for one patient; patient tested positive by ISH; 3. By independent review committee in the modified FAS, which includes patients who received ≥1 dose of trastuzumab pamirtecan and had at least one measurable lesion as assessed by IRC at baseline according to RECIST v1.1; 4. Defined as complete response + partial response + stable disease for 5 weeks or longer; 5. Includes patients who received ≥1 dose of trastuzumab pamirtecan. Phase 3 confirmatory study ongoing

------

![](a992bntx1q2026presentati015.jpg)

Development Focus of mRNA Cancer Immunotherapy iNeST and FixVac Portfolios 15 Partnered with: 1. Genentech, a member of the Roche Group; 2. In collaboration with Regeneron. Autogene cevumeran1 BNT113 BNT116 Adjuvant 1L Multiple settings CRC Phase 2 PDAC Phase 2 HPV16+ PD-L1 CPS ≥1 HNSCC Phase 2/3 NSCLC Phase 1 & 2 Monotherapy + Atezolizumab + mFOLFIRINOX + Pembrolizumab Mono & combo with IO & ADCs • Recruitment ongoing • Data presented from epi sub-study at ASCO 2024 and from biomarker sub-study at ESMO-GI 2024 • Recruitment ongoing • Data from Phase 1 trial published: Rojas et al., Nature 2023; Sethna et al., Nature 2025, 6-year data update presented at AACR 2026 • Recruitment ongoing • Trial updated to Phase 2/3 • Recruitment completed in Phase 2 in 1L NSCLC2 • Data presented at SITC 2023, AACR 2024, SITC 2024 and AACR 2026 • Data in frail patients presented at AACR 2025 • Data in patients after CRT presented at WCLC 2025 Phase 2 final analysis expected in 2027 Primary Completion Date in 2031 Phase 3 interim analysis expected in 2026 Individualized Immunotherapy – iNeST1 Off-the-shelf Immunotherapy – FixVac

------

![](a992bntx1q2026presentati016.jpg)

Catalyst-Rich Year Ahead with Multiple Expected 2026 Milestones 16 BioNTech and BMS are focused on maximizing and optimizing pumitamig's potential across tumor types. In response to the evolving treatment landscape, we are adapting previously announced development plans for pumitamig in HNSCC and no longer anticipate a Phase 3 HNSCC trial initiation in 2026. Some data readouts may be event-driven and subject to change based on actual event accrual rates. Partnered with: 1. Bristol Myers Squibb; 2. OncoC4; 3. DualityBio; 4. MediLink; 5. Pivotal trial. Program Trial Readout Phase Indication Late-Stage Trial Readouts Trastuzumab pamirtecan3 Single arm Phase 2 2L+ HER2-expressing endometrial cancer Phase 35 interim analysis Chemo naïve HR+ HER2-low breast cancer Gotistobart2 Phase 35 interim analysis 2L+ sqNSCLC Phase 2 2L+ mCRPC BNT113 Phase 35 interim analysis 1L HPV16+ PD-L1+ HNSCC Pumitamig1 Phase 35 in China interim analysis 1L TNBC Early-Stage Pumitamig & ADC Trial Readouts Pumitamig1 Phase 2 1L NSCLC Phase 2 1L ES-SCLC Phase 2 in China 1L HCC Phase 2 in China 1L MSS-CRC Pumitamig1 + Trastuzumab pamirtecan3 Phase 1/2 Breast cancer Pumitamig1 + BNT324/DB-13113 Phase 2 Advanced solid tumors Phase 1/2 NSCLC/SCLC Pumitamig1 + Sacituzumab drozuntecan3 Phase 2 TNBC Pumitamig1 + BNT326/YL2024 Phase 1/2 NSCLC BNT324/DB-13113 Phase 1/2 2L+ mCRPC Phase 3 Trial Initiations Pumitamig1 Phase 35 1L MSS-CRC 1L HER2- PD-L1+ gastric cancer 1L NSCLC – PD-L1 ≥ 50% Stage III unresectable NSCLC BNT324/DB-13113 Phase 3 1L mCRPC BLA Submission Trastuzumab pamirtecan3 - 2L+ HER2-expressing endometrial cancer Achieved

------

![](a992bntx1q2026presentati017.jpg)

Financial Performance Ramón Zapata, Chief Financial Officer 3 17

------

![](a992bntx1q2026presentati018.jpg)

First Quarter 2026 Financial Results 18 1. All numbers have been rounded and may not add up to the totals. Presentation of the consolidated statements of profit or loss has been condensed. 2. In addition to BioNTech's results determined in accordance with International Financial Reporting Standards ("IFRS"), or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of our business performance (each referred to with the prefix "Adjusted" or, as a whole, "Adjusted Results"). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards,but includes certain adjustments. Reconciliation of the adjusted results to BioNTech's measures based on IFRS Accounting Standards and more information can be found in the appendix and in BioNTech's Report on Form 6-K for the period ended March 31, 2026, filed on May 5, 2026, which is available at www.sec.gov. While non-IFRS measures may offer additional insights, BioNTech's non-IFRS measures are not, and should not be viewed as a substitute for their most directly comparable IFRS Accounting Standards measures, and should always be considered alongside our financial statements prepared in accordance with IFRS Accounting Standards. 3. Cash and cash equivalents plus security investments as of March 31, 2026, reached €16,763.3 million, comprising €9,939.4 million in cash and cash equivalents, €4,696.9 million in current security investments disclosed as financial assets and €2,127.0 million in non-current security investments disclosed as financial assets. In € millions except per share data1 Q1 2026 Q1 2025 IFRS Results Adjusted Results2 IFRS Results Adjusted Results2 Revenues 118 118 183 183 Cost of sales (71) (71) (84) (84) Research and development expenses (557) (527) (526) (526) Sales, marketing, general and administrative expenses (151) (151) (121) (121) Other operating result (16) (9) 13 (2) Operating loss (677) (640) (534) (549) Net loss (532) (495) (416) (431) Diluted loss per share (2.10) (1.95) (1.73) (1.79) €16.8 bnBalance Sheet as of March 31, 2026 – Cash and cash equivalents plus security investments3

------

![](a992bntx1q2026presentati019.jpg)

Reaffirming Full Year 2026 Financial Guidance1 19 1. Excludes risks that are not yet known and/or quantifiable and related activities. Includes effects identified from licensing arrangements, collaborations and Merger & Acquisitions ("M&A") transactions to the extent disclosed. The guidance is based on non-IFRS measures and excludes certain effects compared to measures based on IFRS Accounting Standards. More information can be found in BioNTech's Report on Form 6-K for the period ended March 31, 2026, filed on May 5, 2026, which is available at www.sec.gov. In € millions FY 2026 non-IFRS Guidance Total Revenues 2,000 – 2,300 Adjusted R&D Expenses 2,200 – 2,500 Adjusted SG&A Expenses 700 – 800 Revenue Guidance Considerations • Competitive market dynamics in the United States • Begin managing transition away from multi-year contracts in Europe, and specifically in Germany where BioNTech recognizes direct sales for its COVID-19 vaccine • Stable revenues from the collaboration with BMS, from a pandemic preparedness contract with the German government, and from the BioNTech Group service businesses • No operationally-driven one-time revenue effect, such as from Pfizer opt-out from further development of shingles program

------

![](a992bntx1q2026presentati020.jpg)

Focused Capital Allocation Strategy for Sustainable Value Creation 20 Concentrate investments on advancing BioNTech's growing oncology pipeline toward commercialization, including pumitamig and ADC candidates Enhance operational efficiency with expected cost savings to ramp up over time, reaching approximately €500 million in recurring annual savings upon full implementation of the measures in 20291 Plan to initiate share repurchase program of up to $1.0 billion over the next twelve months Planning Share Repurchase Program Focusing R&D Investments Manufacturing Footprint Consolidation 1. Expected savings relative to BioNTech's 2025 cost base and CureVac's 2026 budget; do not reflect partially offsetting costs for CDMO use or transfer to other sites; and exclude exit costs, which will be recorded as incurred.

------

![](a992bntx1q2026presentati021.jpg)

21 Advanced Strategy, Matured Pipeline and De-risked Development Drive Oncology Execution at Scale and Speed Diversified Multi- Product Company Progress key programs into pivotal stage, leverage partnership with BMS, fortified balance sheet to fund our pipeline Advance combination therapy studies, accelerate pivotal trial execution, build indication-specific oncology portfolios and execute oncology launches Build a diversified, multi-product global immunotherapy powerhouse addressing high unmet medical need of cancer patients worldwide Today 2026-2029 2030 BioNTech Oncology Vision: Translating Science into Survival

------

![](a992bntx1q2026presentati022.jpg)

Thank you

------

![](a992bntx1q2026presentati023.jpg)

Appendix

------

![](a992bntx1q2026presentati024.jpg)

Reconciliation of IFRS to Adjusted Results – Q1 2026 & 2025 Financial Results In € millions except per share data1 Q1 2026 Q1 2025 IFRS Results Non-IFRS Adjustments Adjusted Results2 IFRS Results Non-IFRS Adjustments Adjusted Results2 Revenues 118 - 118 183 - 183 Cost of sales (71) - (71) (84) - (84) Research and development expenses (557) 30 (527) (526) - (526) Sales, marketing, general and administrative expenses (151) - (151) (121) - (121) Other operating result (16) 7 (9) 13 (15) (2) Operating loss (677) 37 (640) (534) (15) (549) Net loss3 (532) 37 (495) (416) (15) (431) Basic and diluted loss per share (2.10) (1.95) (1.73) (1.79) 1. All Numbers have been rounded and may not add up to the totals. Presentation of the consolidated statements of profit or loss has been condensed. 2. In addition to BioNTech's results determined in accordance with International Financial Reporting Standards ("IFRS"), or IFRS Accounting Standards, or IFRS results, BioNTech reports certain adjusted, non-IFRS measures used internally as a supplemental measure of our business performance (each referred to with the prefix "Adjusted" or, as a whole, "Adjusted Results"). The calculation of these measures and the adjusted results as a whole is based on the concepts of the applicable IFRS Accounting Standards, but includes certain adjustments. Reconciliation of the adjusted results to BioNTech's measures based on IFRS Accounting Standards and more information can be found in the appendix and in BioNTech's Report on Form 6-K for the period ended March 31, 2026, filed on May 5, 2026, which is available at www.sec.gov. While non-IFRS measures may offer additional insights, BioNTech's non-IFRS measures are not, and should not be viewed as a substitute for their most directly comparable IFRS Accounting Standards measures, and should always be considered alongside our financial statements prepared in accordance with IFRS Accounting Standards. 3. Tax effects are not considered as part of BioNTech's non-IFRS adjustments. 24

------

![](a992bntx1q2026presentati025.jpg)

BioNTech's Oncology Pipeline 25 Partnered with: 1. Bristol Myers Squibb; 2. Genentech, a member of the Roche Group; 3. DualityBio; 4. OncoC4; 5. MediLink; 6. Genmab; 7. In collaboration with Regeneron; 8.Trial ongoing in China only; 9.Trial is currently being conducted by or on behalf of BioNTech. Bristol Myers Squibb holds co-exclusive rights to pumitamig. Phase 1 Phase 1/2 Phase 2 Phase 2/3 Phase 3 BNT116 Adv. NSCLC BNT3214 Multiple solid tumors Pumitamig1 1L adv./met. TNBC8 Trastuzumab pamirtecan3 Multiple solid tumors Autogene cevumeran2 Adj. CRC Pumitamig1 2L ES-SCLC8 Pumitamig1 or Sacituzumab drozuntecan + BNT324/DB-13113 Multiple solid tumors9 BNT113 1L HPV16+ HNSCC BNT324/ DB-13113 Met. CRPC Trastuzumab pamirtecan3 Met. BC BNT211 Multiple solid tumors BNT324/ DB-13113 Multiple solid tumors Pumitamig1 + BNT314/GEN10596 Met. CRC9 Autogene cevumeran2 Adj. PDAC Pumitamig1 2L+ EGFRm NSCLC8 Pumitamig1 1L met. CRC Gotistobart4 Met. NSCLC Trastuzumab pamirtecan3 2L EC BNT314/GEN10596 Multiple solid tumors Sacituzumab drozuntecan3 Multiple solid tumors Pumitamig1 + BNT3212 Multiple solid tumors BNT1167 1L adv. NSCLC Pumitamig1 2L Glioblastoma8 Pumitamig1 1L met. Gastric Pumitamig1 1L ES-SCLC BNT317 Multiple solid tumors BNT329 Multiple solid tumors Pumitamig1 + BNT3213 1L HCC8,9 BNT326/YL2025 Multiple solid tumors8 Pumitamig1 1L HCC8 Pumitamig1 1L NSCLC Pumitamig1 1L adv. NSCLC BNT326/YL2025 Multiple solid tumors Gotistobart4 Met. CRPC Pumitamig1 + BNT324/DB-13113 Adv./met. NSCLC and SCLC9 BNT326/YL2025 Adv./met. BC8 Pumitamig1 1L MPM8 Pumitamig1 Unresectable Stage III NSCLC Gotistobart4 Multiple solid tumors Pumitamig1 + Sacituzumab drozuntecan3 Multiple solid tumors9 Gotistobart4 PROC Pumitamig1 2L NEN8 Pumitamig1 2L SCLC8 Pumitamig1 Multiple solid tumors8 Pumitamig1 + BNT326/YL2025 Multiple solid tumors Pumitamig1 1L met. CRC8 Pumitamig1 2L adv./met. NSCLC Pumitamig1 1L adv./met. TNBC Pumitamig1 1L adv. HCC Pumitamig1 + BNT326/YL2025 Adv. NSCLC Pumitamig1 1L ES-SCLC8 Pumitamig1 1L met. PDAC8 Pumitamig1 1L adv./met.TNBC8 Pumitamig1 Adv. RCC Pumitamig1 + Trastuzumab pamirtecan3 Adv./met. BC9 Pumitamig1 1L/2L+ ES-SCLC Pumitamig1 1L/2L adv./met. TNBC mRNA immunotherapy Next generation immunomodulator Targeted therapy Novel-novel combination PLANNED

------

![](a992bntx1q2026presentati026.jpg)

26 Partnered with: 1. University of Pennsylvania; 2. Pfizer; 3. Fosun Pharma; 4. Funded by the Gates Foundation; 5. Funded by the Coalition for Epidemic Preparedness Innovations (CEPI). mRNAAntibody BioNTech's Infectious Diseases Pipeline Phase 1 Phase 1/2 Phase 2 Commercial BNT1631 HSV BNT162 + BNT1612 COVID-19 – Influenza combination BNT1665 Mpox BNT1622,3 COVID-19 BNT351 HIV BNT1644 Tuberculosis BNT165 Malaria

------

![](a992bntx1q2026presentati027.jpg)

Abbreviation Directory 27 n L nth line ESMO European Society for Medical Oncology mRNA Messenger ribonucleic acid AACR American Association for Cancer Research FAS APO-1 or CD95 MSS Microsatellite stability ADC Antibody-drug conjugate FixVac Fixed Antigen Vaccine NE Not evaluable for response adj. Adjuvant FY Fiscal year NEN Neuroendocrine neoplasm adv. Advanced G7 markets Canada, France, Germany, Italy, Japan, GB, USA NR Not reached ASCO American Society of Clinical Oncology GB Great Britain (sq) NSCLC (squamous) Non-small cell lung cancer BC Breast cancer GI Gastrointestinal (c)ORR (confirmed) Objective response rate BLA Biologics License Applications HCC Hepatocellular carcinoma OS Overall survival BMS Bristol Myers Squibb HER2 (or 3) Human epidermal growth factor receptor 2 (or 3) PD-(L)1 Programmed cell death protein (ligand) 1 CEPI Coalition for Epidemic Preparedness HIV Human immunodeficiency virus PDAC Pancreatic ductal adenocarcinoma Innovations HNSCC Head and neck squamous cell carcinoma PFS Progression-free survival CDMO Contract Development and Manufacturing HPV 16 Human papilloma virus 16 PoC Proof of concept Organization HR Hormone receptor PROC Platinum-resistant ovarian cancer CI Confidence interval HSV Herpes simplex virus R&D Research and development CPI Checkpoint inhibitor ICI Immune checkpoint inhibitor RCC Renal cell carcinoma CPS Combined positive score IFRS International financial reporting standards RECIST Response Evaluation Criteria in Solid Tumors CRC Colorectal cancer IHC Immunohistochemistry (ES)SCLC (Extensive stage) small cell lung cancer (m)CRPC (met.) Castration resistant prostate cancer IIT Investigator initiated trial SEC Securities and Exchange Commission CRT Chemoradiation therapy iNeST Individualized NeoAntigen-Specific Therapy SG&A Selling, general and administrative expenses ctDNA Circulating tumor DNA IO Immuno-oncology SITC Society of Immunotherapy of Cancer DCR Disease control rate IRC Independent Review Committee (n)sq (non-)squamous (m)DoR (median) Duration of response ISH In-situ hybridyzation TCE T cell engager EC Endometrial cancer M&A Merger and acquisitions TM Trademark EGFR(m) (mutated) Epidermal growth factor receptor met. Metastatic TNBC Triple-negative breast cancer ELCC European Lung Cancer Congress MPM Malignant pleural mesothelioma WCLC World Conference of Lung Cancer epi Epidemiology Mpox Monkey pox

------